New head-to-head data ( phase IV IXORA-R study) show Taltz superiority versus Tremfya in people with moderate to severe plaque psoriasis.- Eli Lilly

Eli Lilly and Company presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase IV IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint.

Taltz met the primary endpoint of superiority vs. Tremfya in the proportion of patients with moderate to severe plaque psoriasis achieving complete skin clearance as measured by PASI 100 at Week 12, as well as key secondary endpoints. The study is ongoing through Week 24. A total of 1,027 patients with moderate to severe plaque psoriasis were enrolled in the study to evaluate the efficacy and safety of Taltz compared to Tremfya.

Participants were randomized to receive Taltz or Tremfya at the approved dose for a total of 24 weeks, with the primary analysis conducted at 12 weeks. In IXORA-R, the safety profiles of Taltz and Tremfya were consistent with those previously reported for both treatments. As the IXORA-R study is ongoing, not all data will be presented at this meeting to prevent unblinding for investigators and participants. Lilly plans to share results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks in 2020.